Narrative review / 2022
A review argues that statin therapy for primary cardiovascular prevention does not reduce mortality and has limited net benefit compared to lifestyle changes.
This review evaluates the evidence regarding statin therapy for the primary prevention of cardiovascular disease. The author states that prescribing statins to healthy patients without cardiovascular disease does not extend life and yields only a marginal reduction in ischemic event risk, while causing numerous side effects. In elderly patients, statin therapy shows no reduction in mortality or ischemic events and carries potential for significant harms. The review concludes that strategies should prioritize improving lifestyle factors rather than focusing on cholesterol levels and pharmacological intervention.
- Study type
- Narrative review
- Who was studied
- Healthy patients without cardiovascular disease, including elderly patients
- What was measured
- Mortality, ischemic events, side effects, and net benefit of statins
THE PAPER
Statin therapy for the primary prevention of cardiovascular disease: Cons.
Durai V, Redberg RF. Atherosclerosis, 2022.
PubMed 35934533 ↗DOI 10.1016/j.atherosclerosis.2022.07.003 ↗
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.